Marshall Urist

EVP, Research & Investments

Marshall Urist (EVP, Research & Investments) filed 14 Form 4 reports in the trailing twelve months (0 purchases, 14 sales), most often in Royalty Pharma plc (RPRX). The largest single filing was $1.7M of RPRX (41,575 sh across 2 lots, as filed), executed Dec 1 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 14 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$12.1M

shares × price, as filed

Last traded

Jul 1

Filed Jul 2

Median ADV $206.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $12.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 14 filings

Sector per market data · by filing · past 12 months

Most traded names

RPRX

Royalty Pharma plc RPRX · 0 buys · 14 sells 14 filings

Recent filings

RPRXSALE Royalty Pharma plc View filing → $770K
20,000 sh × $38.48
Exec Jan 2
Filed Jan 6 · 5:30 PM ET RPRXSALE Royalty Pharma plc View filing → $786K
20,000 sh × $39.32
Exec Dec 26 2025
Filed Dec 29 2025 · 5:30 PM ET RPRXSALE Royalty Pharma plc View filing → $768K
20,000 sh × $38.38
Exec Dec 19 2025
Filed Dec 22 2025 · 5:30 PM ET RPRXSALE Royalty Pharma plc View filing → $766K
20,000 sh × $38.32
Exec Dec 16 2025
Filed Dec 17 2025 · 5:30 PM ET RPRXSALE Royalty Pharma plc View filing → $1.6M
41,576 sh across 2 lots
Exec Dec 5 2025
Filed Dec 9 2025 · 5:30 PM ET RPRXSALE Royalty Pharma plc View filing → $1.7M
41,575 sh across 2 lots
Exec Dec 1 2025
Filed Dec 3 2025 · 5:30 PM ET